Likely uptake of a future a lung cancer screening programme in Hodgkin lymphoma survivors: a questionnaire study
Affiliation
Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UKIssue Date
2022
Metadata
Show full item recordAbstract
Background: Many Hodgkin lymphoma (HL) survivors are at increased risk of subsequent malignant neoplasms (SMN), including lung cancer, due to previous treatment for HL. Lung cancer screening (LCS) detects early-stage lung cancers in ever smokers but HL survivors without a heavy smoking history are ineligible for screening. There is a rationale to develop a targeted LCS. The aim of this study was to investigate levels of willingness to undergo LCS in HL survivors, and to identify the psycho-social factors associated with screening hesitancy. Methods: A postal questionnaire was sent to 281 HL survivors registered in a long-term follow-up database and at increased risk of SMNs. Demographic, lung cancer risk factors, psycho-social and LCS belief variables were measured. Multivariable logistic regression analysis was performed to determine the factors associated with lung cancer screening hesitancy, defined as those who would 'probably' or 'probably not' participate. Results: The response rate to the questionnaire was 58% (n = 165). Participants were more likely to be female, older and living in a less deprived area than non-participants. Uptake (at any time) of breast and bowel cancer screening among those previously invited was 99% and 77% respectively. 159 participants were at excess risk of lung cancer. The following results refer to these 159. Around half perceived themselves to be at greater risk of lung cancer than their peers. Only 6% were eligible for lung cancer screening pilots aimed at ever smokers in the UK. 98% indicated they would probably or definitely participate in LCS were it available. Psycho-social variables associated with LCS hesitancy on multivariable analysis were male gender (OR 5.94 CI 1.64-21.44, p < 0.01), living in an area with a high index of multiple deprivation decile (deciles 6-10) (OR 8.22 CI 1.59-42.58, p < 0.05) and lower levels of self-efficacy (OR 1.64 CI 1.30-2.08 p < 0.01). Conclusion: HL survivors responding to this survey were willing to participate in a future LCS programme but there was some hesitancy. A future LCS trial for HL survivors should consider the factors associated with screening hesitancy in order to minimise barriers to participation.Citation
Broadbent R, Armitage CJ, Crosbie P, Radford J, Linton K. Likely uptake of a future a lung cancer screening programme in Hodgkin lymphoma survivors: a questionnaire study. Vol. 22, BMC Pulmonary Medicine. Springer Science and Business Media LLC; 2022.Journal
BMC Pulmonary MedicineDOI
10.1186/s12890-022-01959-3PubMed ID
35484621Additional Links
https://dx.doi.org/10.1186/s12890-022-01959-3Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1186/s12890-022-01959-3
Scopus Count
Collections
Related articles
- The perspectives of survivors of Hodgkin lymphoma on lung cancer screening: A qualitative study.
- Authors: Broadbent R, Gorman L, Armitage CJ, Radford J, Linton K
- Issue date: 2022 Feb
- Pilot study of lung cancer screening for survivors of Hodgkin lymphoma.
- Authors: Broadbent R, Crosbie P, Armitage CJ, Taylor B, Tenant S, Mercer J, Radford J, Linton K
- Issue date: 2024 Oct 1
- The development of a decision aid to support Hodgkin lymphoma survivors considering lung cancer screening.
- Authors: Broadbent R, Seale T, Armitage CJ, Linton K
- Issue date: 2022 Feb 1
- Low-dose chest computed tomography for lung cancer screening among Hodgkin lymphoma survivors: a cost-effectiveness analysis.
- Authors: Wattson DA, Hunink MG, DiPiro PJ, Das P, Hodgson DC, Mauch PM, Ng AK
- Issue date: 2014 Oct 1
- Patient-Provider Lung Cancer Screening Discussions: An Analysis of a National Survey.
- Authors: Nourmohammadi N, Liang THP, Sadigh G
- Issue date: 2024 Jun